Abstract

BackgroundRemifentanil, an ultra-short-acting opioid, is widely used for pain control during surgery. However, regular dose (RD) remifentanil exacerbates postoperative pain in a dose-dependent manner. Recent studies suggest that high-dose (HD) remifentanil offers sustained analgesia in experimental studies. We thus hypothesized that intraoperative administration of high-dose remifentanil may attenuate postoperative pain.MethodsIn this prospective, randomized, double blind, controlled clinical study, sixty patients undergoing thyroidectomy (18–60 years-of-age) received an intraoperative infusion of 0.2 (RD group) or 1.2 μg kg−1min−1 (HD group) remifentanil during thyroidectomy. A visual analogue scale (VAS) was used to measure pain intensity. Mechanical pain threshold on the forearm was assessed using von Frey filaments before surgery (baseline), 2 h postoperatively and 18–24 h postoperatively. The primary outcome was to compare the difference of VAS score at different time points after operation and morphine consumption 24 h postoperatively between RD and HD groups. The second outcome was to compare the difference of mechanical pain thresholds in the forearm postoperatively between RD and the HD groups.ResultsVAS scores were lower 30 min postoperatively in the HD group (1.29±1.67, 95% CI 0.64–1.94) compared with the RD group (2.21±1.67, 95% CI 1.57–2.84) (t = 3.427, p = 0.0043, RD group vs. HD group). Postoperative morphine consumption was much lower in the HD group compared with the RD group (1.27±1.88 mg vs. 0.35±1.25 mg, p = 0.033). In both groups, mechanical pain threshold was decreased 18–24 h postoperatively (2.93±0.209 Ln(g) vs. 3.454±2.072 Ln(g), p = 0.032 in RD group; 2.910±0.196 Ln(g) vs. 3.621±0.198 Ln(g), p = 0.006 in HD group, 18–24 h postoperatively vs baseline).ConclusionsIntraoperative administration of high-dose remifentanil decreased VAS scores and morphine consumption postoperatively. Thus, modulation of intraoperative opiates may be a simple and effective method of postoperative pain management.Trial RegistrationThis trial is registered in ClinicalTrials.gov, with the Name: Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy, and ID number: NCT01761149.

Highlights

  • Remifentanil, a potent ultra-short-acting m-opioid agonist, is a widely used analgesic in clinical anesthesia due to its rapid onset of action and clearance after withdrawal

  • Of the 57 enrolled, 29 patients were randomized to the regular dose (RD) group; 28 patients were randomized to the HD group

  • At 30 min postoperatively, visual analogue scale (VAS) scores were significantly higher in the RD group (2.2161.67, 95% CI 1.57–2.84) compared to the HD group (1.2961.67, 95% CI 0.64–1.94) (t = 3.427, p = 0.0043, Two-way ANOVA followed by Bonferroni’s test)

Read more

Summary

Introduction

Remifentanil, a potent ultra-short-acting m-opioid agonist, is a widely used analgesic in clinical anesthesia due to its rapid onset of action and clearance after withdrawal. In a more recent study, an intraoperative infusion of remifentanil (0.2 mg kg21min21) caused greater pain sensitivity and greater visual analogue scale (VAS) scores than in those who received an infusion of 0.05 mg kg21min21 [4]. In another recent study, investigators reported that after laparoscopic ureteroneocystostomy, pediatric patients who intraoperatively received 0.6 mg kg21min and 0.9 mg kg21min of remifentanil required more fentanyl postoperatively than those who received saline or 0.3 mg kg21min remifentanil [5]. Regular dose (RD) remifentanil exacerbates postoperative pain in a dose-dependent manner. We hypothesized that intraoperative administration of high-dose remifentanil may attenuate postoperative pain

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.